Patricia M. Meehan

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

Lisa M. Demeter, Robert W. Shafer, Patricia M. Meehan et al. · Antimicrobial Agents and Chemotherapy · 2000 · 88 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

A stochastic differential equation model of diurnal cortisol patterns

Emery N. Brown, Patricia M. Meehan, Arthur P. Dempster · American Journal of Physiology-Endocrinology and Metabolism · 2001 · 61 citations

Life Sciences, Endocrinology, Physiology +15

A Phase-I Study of the Safety, Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin in Patients with HIV-1 Disease

Anthony J. Japour, Juan J.L. Lertora, Patricia M. Meehan et al. · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · 1996 · 49 citations

Medicine, Pharmacokinetics, Pharmacology +17

HIV-1 Drug Susceptibilities and Reverse Transcriptase Mutations in Patients Receiving Combination Therapy with Didanosine and Delavirdine

Lisa M. Demeter, Patricia M. Meehan, Gene D. Morse et al. · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · 1997 · 39 citations

Life Sciences, Pharmacokinetics, Pharmacology +17

ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

Michael F. Para, Patricia M. Meehan, Jeanne Holden‐Wiltse et al. · Antimicrobial Agents and Chemotherapy · 1999 · 32 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17